2791

View Abstract / View Presentation

Tracking longitudinal disease progression of MS during fingolimod therapy using SFCI, a combined structural and functional connectivity metric

Pallab K Bhattacharyya¹, Robert Fox¹, Jian Lin¹, Paola Raska¹, Ken Sakaie¹, and Mark J Lowe¹
¹Cleveland Clinic Foundation, CLEVELAND, OH, United States

SFCI, a combined structural and functional connectivity metric (derived by combining DTI and functional connectivity measures), is a sensitive imaging-based measure of disease progression of multiple sclerosis following clinical intervention.

Fig. 3. Combined structural and functional connectivity for (a) motor, (b) cognitive pathways and (c) pathway-combined SFCI evolution over 24 months of fingolimod therapy.

Fig. 1. Equations for calculating motor- and cognitive-pathway specific combined connectivity measures (Eq. 1 and 2) and SFCI (Eq. 3). SMC: motor pathway, FP: cognitive pathway, f_c: functional connectivity, TD: transverse diffusivity.